09/11/07

Quigley Corporation Releases Update on Quigley Pharma's Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy

08/01/07

Quigley Evaluates Regulatory and Market Opportunities for Anti-Inflammatory / Cytokine Modifying Compound

07/30/07

Quigley Begins Human Trial to Investigate Effects of Broad Spectrum Anti-Inflammatory Compound on Metabolic Syndrome Patients

 

More +

In 2005, the world finally awoke to the possibility of a global influenza pandemic as the avian flu virus spread across Asia into Africa and Europe.  But avian flu was hardly the only health concern in the headlines: the continuing diabetes epidemic, the growing threat of nuclear terrorism, and additional warnings on common pain relievers also dominated.

Enter Quigley Pharma. With a growing pipeline, the Company is developing numerous compounds to address several major health issues facing the world today.

+ More

8.03.06

SEC Filing

2006

Download 2006 Annual Report

+ More